Under the deal, Theradiag will have access to Immunodiagnostic's IDS-i10 automation system, and Immunodiagnostic will distribute Theradiag tests in 33 countries.
Symbolized by its first time exhibiting at HIMSS, Roche Diagnostics is using data to bridge the worlds of imaging, sequencing, diagnostics, drug discovery, and treatment.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
The firm said that its cell-free DNA assay has shown a high positive predictive value in preliminary clinical studies involving stage IV colorectal cancer patients.
In a newly published study, an algorithm developed at NIH shows promise for improving early detection of cervical cancer in low-resource areas, where 80 percent of cases occur.
Run by the daughter of a renowned genetic oncologist, CancerIQ is expanding and raising money as it rolls out its testing management and clinical decision support technology.
The company published data from a 1,102-patient trial that found that amino acid markers could be useful for diagnosing the condition in a subset of patients.
With a University of Missouri partnership, Roche is testing the combination of data from disparate sources and furthering the integration of several recent acquisitions.
Pro-Lab will shepherd Medicortex's kit through the regulatory processes in Canada and the UK, as well as clinically validate it. It will have exclusive rights to sell the kit in the two nations.
The firm expects to build out a menu for the reader, which will automate results reporting for colorimetric- and fluorescence-based tests.